US Stem Cell Clinics, Patient Safety, and the FDA
By Leigh Turner,
Trends in Molecular Medicine
| 05. 01. 2015
Untitled Document
Clinics advertising adipose-derived autologous ‘stem cell treatments’ are proliferating across the USA. The rapid spread of businesses promoting unapproved stem cell interventions reveals a widening gulf between federal regulations governing stem cell based therapies and a marketplace where few companies selling such interventions are subjected to regulatory action. Fatal outcomes, complications, and lawsuits have not slowed this rush to the marketplace [1, 2, 3, 4].
Cell Surgical Network (CSN) is the most visible example of the emergence of US businesses selling unlicensed stem cell interventions. CSN is an association of over 50 clinics promoting adipose-derived ‘stem cell treatments’ for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, muscular dystrophy, stroke, cardiomyopathy, and many other diseases and injuries. Another company, StemGenex, promotes access to commercial ‘stem cell therapy studies’ for Alzheimer's disease, multiple sclerosis, type I and type II diabetes, Crohn's disease, and other illnesses. Between 100 and 200 such businesses are estimated to be operating in the USA [5]. The multiplication of such clinics represents a dramatic shift in which individuals can...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
